GLB-001 for blood cancers that have returned or not responded
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing a new drug called GLB-001 for people with certain blood cancers or bone marrow disorders that have not gotten better with standard treatments. The goal is to see if the drug is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a blood cancer or bone marrow disorder (like myelofibrosis, polycythemia vera, essential thrombocythemia, myelodysplastic syndrome, or acute myeloid leukemia) that has not responded to treatment, has come back, or you cannot tolerate the side effects.
- You must be able to take care of yourself or need only a little help with daily activities (ECOG score 0-2).
- Your major organs (blood, liver, kidneys) must be working well enough.
- You must not have had certain other cancer treatments or procedures within a specific time period before starting the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
This study tests a new drug called BG-75202, alone or combined with other treatments, for myeloid malignancies (blood cancers affecting bone marrow cells) that have returned or stopped responding to previous treatment. The goal is to see if this drug can help control the cancer.
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
This early-phase study tests BGB-11417 in people with certain bone-marrow (blood) cancers such as AML, MDS, or MDS/MPN. The goal is to find out how the medicine works and whether it can control the cancer.
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
This early-stage study tests a new medicine (BGB-16673) that targets B-cell cancer cells in people with specific lymphoma or related blood cancers. It aims to see how well the drug can control the cancer and what side effects it causes, especially in Chinese participants.
Hear when a new Polycythemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.